PPAR-γ Impairment Alters Peroxisome Functionality in Primary Astrocyte Cell Cultures
Figure 4
Catalase activity: effect of rosiglitazone on G3335-induced enzymatic impairment. Astrocytes (2 105 cells/well) were treated with the reversible PPARγ antagonist G3335 (30 μM) for (a) 2 days or (b) 5 days, in the absence or presence of the PPARγ agonist rosiglitazone (100 μM). Catalase activity was measured on days 0, 2, and 5. Values are expressed as the mean ± S.E.M. percent of control of three experiments. Control catalase activity (day 0) was arbitrarily set as 100%. * in comparison to control conditions in the absence of treatment on day 0; in comparison to control on days 2 (a) or 5 (b).
